Aliskiren prevents and ameliorates metabolic syndrome in fructose-fed rats


Abstract

The renin-angiotensin system plays a major role in the pathogenesis of metabolic syndrome. The objective of this study was to examine the effects of aliskiren, a direct renin inhibitor, on the metabolic syndrome of fructose-fed rats.

Material and methods: Male Sprague-Dawley rats were divided into 4 groups (n = 6 for each group). Group Con: rats were fed a standard chow diet for 8 weeks, group Fru: rats were fed a high fructose diet (60% fructose) for 8 weeks, group FruA: rats were fed a high fructose diet and were co-infused with aliskiren (100 mg/kg/day), and group FruB: rats were treated as group Fru, but aliskiren was administered 4 weeks later. Systolic blood pressure (SBP), homeostasis model assessment-insulin resistance (HOMA-IR), and blood profiles were measured.

Results: By the end of week 4 and 8 of a high fructose diet, SBP had increased significantly from 111 ±5 to 142 ±4 and 139 ±5 mmHg (p < 0.05), respectively. A high fructose diet significantly increased HOMA-IR from baseline (6.15 ±1.59) to 21.25 ±2.08 and 21.28 ±3.1 (p < 0.05) at week 4 and 8, respectively, and significantly induced metabolic syndrome. Concurrent aliskiren treatment prevented the development of hypertension and metabolic syndrome in fructose-fed rats. When fructose-induced hypertension was established, subsequent aliskiren treatment for 4 weeks reversed the elevated SBP and ameliorated metabolic syndrome. There were no significant differences in food, water intake, urine flow or body weight gain among groups.

Conclusions: Aliskiren not only prevents but also ameliorates metabolic syndrome in fructose-fed rats.

Key words: aliskiren, direct renin inhibitor, fructose, hypertension, metabolic syndrome.

Introduction

Metabolic syndrome, a worldwide issue, has been regarded as the existing development of overall and central obesity, impaired glucose tolerance, dyslipidaemia (combination of low levels of high-density lipoproteins, high levels of triglycerides, low levels of high-density lipoproteins, and high levels of insulin resistance).
lipoprotein cholesterol and high levels of triglycerides), and hypertension [1, 2]. Similarly, emerging data suggest that experimental fructose consumption tends to produce some of the changes associated with metabolic syndrome even without increasing body weight [3]. The detrimental metabolic processes related to fructose consumption seem limited to obesity-pathway mechanisms [3]. Therefore, this animal model of fructose-fed rats is popularly utilized to study the metabolic disturbances and hypertension, independent of obesity or genetic contributions.

It is well recognized that the renin-angiotensin system (RAS) plays an important physiological role in the control of body fluid and blood pressure homeostasis, through its effects on cardiovascular, renal and neural functions [4]. Our previous studies demonstrated that angiotensin (Ang) converting enzyme (ACE) inhibitor and Ang II type 1 receptor blockers (ARB) reduce blood pressure and improve insulin sensitivity in hyperinsulinaemia-induced hypertensive rats [5, 6]. These results are consistent with reports by others [7, 8]. For example, recent clinical trials demonstrated that the use of an ACE inhibitor and ARB significantly reduced the risk of developing diabetes compared with other classes of antihypertensive agents [7, 8], indicating that inhibition of the RAS may contribute to the improvement of insulin resistance. Similarly, Aliskiren, a renin inhibitor, has been demonstrated to reduce blood pressure in spontaneously hypertensive rats [9], essential hypertensive patients and type 2 diabetes with hypertension [10, 11]. Further, the effects of aliskiren on the metabolic syndrome are currently under investigation. Therefore, we undertook this study to evaluate the effects of aliskiren on the metabolic syndrome in rats fed with a high fructose diet.

Material and methods

Animals

Male Sprague-Dawley rats initially weighing 200 g to 230 g were used for the experiments. All experimental procedures were carried out in accordance with prior approval of the institutional Animal Care and Use Committee of Tzu Chi University (TCU 98-05). Rats were kept in a room with air maintained at a temperature of 24-27°C, humidity of 50-80% and a 12-h light/dark cycle, and had access to tap water ad libitum throughout the experiments.

The standard chow diet was composed of 50% starch, 21% protein, 4% fat, 4.5% cellulose, and standard vitamins and mineral mix. The high fructose diet (Harlan Teklad, Madison, WI) was composed of 60% fructose, 21% protein, 5% fat, 8% cellulose, and standard vitamins and mineral mix.

Experimental protocols

After a control period of 1 week, rats were divided into 4 groups (n = 6 for each group). Group Con: rats were fed a standard chow diet for 8 weeks and served as the control group, group Fru: rats were fed a high fructose diet for 8 weeks, group FruA: rats were fed a high fructose diet and were co-infused with aliskiren (100 mg/kg per day, a kind gift of Novartis Pharmaceuticals, Basel, Switzerland) via a subcutaneous osmotic minipump, and group FruB: rats were treated as group Fru, but aliskiren (100 mg/kg per day) was administered 4 weeks later. The first day of fructose feeding was recognized as day 1.

Body weight was measured twice a week. The systolic blood pressure (SBP) was measured twice a week by the tail-cuff method. Blood samples (1 ml) for glucose, insulin, triglycerides, and total cholesterol were taken after 12 h of fasting at day 0, midpoint (day 28), and at the end of the study (day 56) from the femoral artery under sodium pentobarbital anaesthesia (40 mg/kg, IP). Plasma was separated, divided into aliquots, and frozen until analysis.

In order to assess insulin resistance of animals, homoeostasis model assessment-insulin resistance (HOMA-IR) was determined at day 0, day 28, and day 56 of fructose treatment.

Measurements for systolic blood pressure

Rats were removed from the animal room and were taken to the laboratory at 8 AM; they were allowed free access to water and were kept in a quiet area before SBP was measured at 9 AM. The tail-cuff method without heating was used to measure SBP with the use of a programmed electrophysmomanometer (MK-2000ST, Muro-machi, Tokyo, Japan) as described previously [5, 6]. The mean of 6 consecutive readings was used as the measurement of SBP of each rat for that day, and SBP was determined twice a week during the control (1 week) and experimental (8 weeks) periods.

Osmotic minipump installation

The osmotic minipump installation was done as in our previous studies [5, 6]. In brief, when aliskiren was administered to rats, an osmotic minipump (No. 2002, 14 days of active life, Alza Corp) was filled with the agent, which was dissolved in normal saline, and was implanted subcutaneously in rats under brief anaesthesia with ketamine (60 mg/kg, IP) and xylazine (7.5 mg/kg, IP). Aqueous penicillin (5000 U/kg SC) was administered immediately after minipump implantation. At the end of the life of the minipump, a new minipump was implanted and the used one removed. The residual volume in each minipump was flushed with saline.
minipump removed was carefully examined to ensure that the minipump release function was normal.

**Homeostatic model assessment-insulin resistance (HOMA-IR)**

Insulin resistance was assessed via HOMA-IR, and was determined at day 0, day 28, and day 56. HOMA-IR was calculated using this formula: \[
\text{HOMA-IR = \frac{[\text{plasma glucose (mmol/l)} \times \text{insulin (mU/ml)}]}{22.5}}
\]

**Laboratory measurements**

The blood samples were immediately centrifuged at 4000 g at 4°C for 10 min. The plasma samples were separated and subjected to immediate assays of glucose, insulin, triglycerides and total cholesterol. Plasma levels of glucose, triglycerides (TG) and total cholesterol were measured with a COBAS Integra 800 analyser (Roche Diagnostics, USA). Plasma insulin was measured by automated chemiluminescence immunoassay via an ADVIA Centaur analyser (Bayer, Germany).

**Statistical analysis**

All results were presented as mean ± SD. Experimental data over time were analysed by two-way analysis of variance (ANOVA) (the first factor being the treatment group and the second the time period) for comparison between groups. When a significant effect was detected by ANOVA, the Newman-Keuls test was used to establish which difference between means reached statistical significance. Student’s t-test for unpaired data was also performed when appropriate. Value of \( p < 0.05 \) was considered statistically significant.

**Results**

**Aliskiren prevents and reduces the rise of SBP in fructose-fed rats**

The changes in SBP of control rats and fructose-fed rats with or without aliskiren treatment are illustrated in Figure 1. In control rats, SBP did not change significantly throughout the experimental period. However, high fructose diet alone significantly increased the SBP from 111 ±5 mmHg during the control period to 142 ±4 and 139 ±5 mmHg by the end of the 4th and 8th weeks, respectively. Concomitant aliskiren treatment prevented the rise of SBP in fructose-fed rats, and the levels were not significantly different from those of control rats at each corresponding time point. When fructose-induced hypertension had been established (from 112 ±4 mmHg to 141 ±3 mmHg, \( p < 0.05 \)) in rats fed fructose for 4 weeks, subsequent aliskiren treatment for 4 weeks reversed the elevated SBP to the control levels.

**Aliskiren does not alter the food intake, water intake, urine flow or body weight gain in fructose-fed rats**

Effects of aliskiren on food intake, water intake, urine flow and body weight gain of fructose-fed rats are shown in Figure 2. There were no significant differences in food, water intakes, urine flow or body weight gain among groups at the corresponding time periods.

**Aliskiren prohibits and ameliorates hyperglycaemia, hyperinsulinaemia, hypertriglyceridaemia and hypercholesterolaemia in fructose-fed rats**

Table I summarizes the effects of a high fructose diet alone and in combination with aliskiren on plasma glucose, insulin, triglycerides and total cholesterol. Fructose-fed rats significantly increased plasma glucose, insulin, triglyceride and total cholesterol compared to control rats throughout the experiments. Concurrent aliskiren treatment
interrupted the rise of plasma glucose, insulin, triglycerides and total cholesterol in fructose-fed rats, and the levels were not significantly different from those of control rats at each corresponding time point. In addition, a high fructose diet for 4 weeks induced hyperglycaemia, hyperinsulinaemia, hypertriglyceridaemia and hypercholesterolemia, and subsequently in combination with aliskiren treatment for 4 weeks reversed these elevated parameters to the control levels.

Aliskiren suppresses and improves insulin resistance in fructose-fed rats

The effect of aliskiren on insulin resistance of fructose-fed rats is presented in Figure 3. There were no significant differences in HOMA-IR values (between 6.417 ±0.99 and 6.35 ±1.25) in control rats throughout the experiments. A high fructose diet significantly increased HOMA-IR values from baseline (6.15 ±1.59) to 21.25 ±2.08 and 21.28 ±3.1 at day 28 and 56, respectively, p < 0.05) than those of control rats and pre-fructose feeding. The levels of HOMA-IR (between 5.98 ±1.14 and 7.05 ±0.93) in fructose-fed rats with concomitant aliskiren treatment were not significantly different from those of control rats at each corresponding time point. Furthermore, when fructose-induced higher HOMA-IR level had been established (from 6.2 ±0.67 to 19.97 ±3.93, p < 0.05), subsequent treatment with aliskiren for 4 weeks inverted the elevated HOMA-IR to the control levels (from 19.97 ±3.93 to 6.37 ±0.92, p < 0.05).

Discussion

In this rat model of fructose-fed diet, we have demonstrated that a high fructose diet elicits the elevation of plasma glucose, insulin, triglycerides, total cholesterol as well as SBP. These results, consistent with reports by others [12–14], support the view that a sustained fructose-fed diet causes hypertensive insulin resistance in rats. Moreover, we found that administration of aliskiren, a direct renin inhibitor, not only prevented but also reversed...
Table I. Effects of high fructose diet alone and in combination with aliskiren on plasma glucose, insulin, triglycerides and total cholesterol

<table>
<thead>
<tr>
<th>Group</th>
<th>N</th>
<th>Day 0</th>
<th>Day 28</th>
<th>Day 56</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Glucose [mmol/l]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Con</td>
<td>6</td>
<td>6.45 ±0.81</td>
<td>6.33 ±0.47</td>
<td>6.90 ±0.20</td>
</tr>
<tr>
<td>Fru</td>
<td>6</td>
<td>6.46 ±0.79</td>
<td>10.54 ±0.89</td>
<td>11.86 ±1.47</td>
</tr>
<tr>
<td>FruA</td>
<td>6</td>
<td>6.42 ±0.68</td>
<td>6.49 ±0.22</td>
<td>7.07 ±0.45</td>
</tr>
<tr>
<td>FruB</td>
<td>6</td>
<td>6.31 ±0.45</td>
<td>10.67 ±1.40</td>
<td>6.74 ±0.41</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Insulin [pmol/l]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Con</td>
<td>6</td>
<td>161.6 ±20.8</td>
<td>155.6 ±19.6</td>
<td>148.4 ±26.7</td>
</tr>
<tr>
<td>Fru</td>
<td>6</td>
<td>153.1 ±30.0</td>
<td>310.0 ±32.2</td>
<td>289.6 ±22.5</td>
</tr>
<tr>
<td>FruA</td>
<td>6</td>
<td>150.8 ±25.6</td>
<td>149.0 ±27.7</td>
<td>161.6 ±24.6</td>
</tr>
<tr>
<td>FruB</td>
<td>6</td>
<td>159.2 ±20.5</td>
<td>301.6 ±36.3</td>
<td>160.3 ±23.0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Triglycerides [mmol/l]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Con</td>
<td>6</td>
<td>1.56 ±0.09</td>
<td>1.60 ±0.10</td>
<td>1.55 ±0.08</td>
</tr>
<tr>
<td>Fru</td>
<td>6</td>
<td>1.60 ±0.15</td>
<td>3.13 ±0.23</td>
<td>3.34 ±0.25</td>
</tr>
<tr>
<td>FruA</td>
<td>6</td>
<td>1.55 ±0.12</td>
<td>1.59 ±0.09</td>
<td>1.72 ±0.21</td>
</tr>
<tr>
<td>FruB</td>
<td>6</td>
<td>1.50 ±0.09</td>
<td>3.15 ±0.17</td>
<td>1.68 ±0.13</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Total cholesterol [mmol/l]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Con</td>
<td>6</td>
<td>2.21 ±0.31</td>
<td>2.27 ±0.14</td>
<td>2.20 ±0.13</td>
</tr>
<tr>
<td>Fru</td>
<td>6</td>
<td>2.25 ±0.17</td>
<td>3.24 ±0.14</td>
<td>3.30 ±0.13</td>
</tr>
<tr>
<td>FruA</td>
<td>6</td>
<td>2.42 ±0.15</td>
<td>2.38 ±0.23</td>
<td>2.31 ±0.15</td>
</tr>
<tr>
<td>FruB</td>
<td>6</td>
<td>2.33 ±0.11</td>
<td>3.16 ±0.20</td>
<td>2.42 ±0.21</td>
</tr>
</tbody>
</table>

**Con** indicates control rats with normal chow diet; **Fru** – fructose-fed diet; **FruA** – fructose-fed diet with concurrent aliskiren administration, **FruB** – fructose-fed diet and further aliskiren administration after 4 weeks of fructose-fed diet; *p < 0.05 vs. day 0, **p < 0.05 vs. control group.

**Figure 3.** Effect of aliskiren on insulin resistance of fructose-fed rats

**Group Con** – rats were fed standard chow diet, **group Fru** – rats were fed high fructose diet, **group FruA** – rats were fed high fructose diet and were co-infused with aliskiren, **group FruB** – rats were treated as group Fru, but aliskiren was administered 4 weeks later. HOMA-IR = homeostasis model assessment of insulin resistance, * and ^ denote p < 0.05 vs. pre-fructose and control rats, respectively, n = 6 for each group.
Similarly, blockade of the effects of Ang II may improve blood flow to insulin-sensitive tissues and increase islet blood flow for an adequate insulin release [30]. Several animal studies have also demonstrated that inhibition of the RAS with an ACE inhibitor or ARB not only prevents but also reduces hypertension, and improves insulin resistance in a high fructose-fed animal model [25, 31]. Furthermore, interruption of the RAS via chronic ACE inhibition or ARB reduces oxidative stress and restores NO production in fructose hypertensive rats [15, 17, 18], which can lead to improved insulin signalling and resistance in pancreas and skeletal muscle [7, 30, 32].

Whether or not inhibition of RAS can blunt the rise of triglycerides in fructose-fed hypertensive rats is still under debate. A study [33] reported that either ACE inhibitor or ET blockade did not decrease the hypertriglyceridaemia in fructose hypertensive rats, although the combination of both inhibitors significantly diminished hypertriglyceridaemia in fructose hypertensive rats. However, another study showed that blockade of the RAS via ACE inhibitor or ARB could reduce hypertension and hypertriglyceridaemia and improve insulin sensitivity [34]. In the present study, aliskiren not only prevented but also reversed hypertriglyceridaemia and hypercholesterolemia to normal levels in fructose hypertensive rats. The mechanism of action for aliskiren is unclear and may be due to downregulation of local RAS in adipose and liver tissue. A recent study in obese mice fed with a high fat diet demonstrated that systemic inhibition of renin via aliskiren elicited a decline of adipose Ang I and Ang II, visceral adiposity and plasma leptin. Furthermore, aliskiren reduced adipose tissue function, and allowed triglycerides to be stored in adipocytes and not in other tissues, and improved insulin resistance [35]. Another study showed that ARB reduced hepatic plasminogen activator inhibitor-1 gene expression, decreased hepatic triglyceride accumulation, and improved insulin resistance [36].

The limitations of this study were the small number of animals in each group and the lack of a vehicle-treated group. In addition, the concentrations of local and systemic Ang II and its correlation with the changes in study variables were not measured.

In conclusion, the present study demonstrates that a high fructose diet significantly induces metabolic syndrome (hypertension, hyperglycaemia, insulin resistance, hypertriglyceridaemia and hypercholesterolaemia) and is independent of changes in food and water intake, urine flow and body weight gain. Aliskiren, a direct renin inhibitor, not only prevents but also reverses the development of metabolic syndrome in rats fed with a high fructose diet. In future, aliskiren-related benefits could be expanded in the clinical setting of the metabolic syndrome. Nevertheless, this remains to be further confirmed by clinical studies.

Acknowledgments

We are thankful to the Taiwan Society of Nephrology for providing 2009 research grants for this study. This study was presented at the 2010 Congress of the European Renal Association – European Dialysis and Transplant Association (Munich, Germany, June 25-28, 2010).

References